Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which lesion to apply which IP treatment will be determined randomly at the time of enrollment using pre-designed block randomization scheme.
Epistemonikos ID: ed57f0a4b7d875f32465a2edf5d999f9848ddc7e
First added on: May 09, 2024